Exelixis Cost Of Revenue vs Interest Expense Analysis

EXEL Stock

USD 22.12 0.19 0.87%

Exelixis financial indicator trend analysis is much more than just examining Exelixis latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Exelixis is a good investment. Please check the relationship between Exelixis Cost Of Revenue and its Interest Expense accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.

Cost Of Revenue vs Interest Expense

Cost Of Revenue vs Interest Expense Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Exelixis Cost Of Revenue account and Interest Expense. At this time, the significance of the direction appears to have no relationship.

The correlation between Exelixis' Cost Of Revenue and Interest Expense is 0.04. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Interest Expense in the same time period over historical financial statements of Exelixis, assuming nothing else is changed. The correlation between historical values of Exelixis' Cost Of Revenue and Interest Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Exelixis are associated (or correlated) with its Interest Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Interest Expense has no effect on the direction of Cost Of Revenue i.e., Exelixis' Cost Of Revenue and Interest Expense go up and down completely randomly.

Correlation Coefficient

0.04

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Exelixis income statement and represents the costs associated with goods and services Exelixis provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Most indicators from Exelixis' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Exelixis current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.At this time, Exelixis' Selling General Administrative is quite stable compared to the past year. Tax Provision is expected to rise to about 32.5 M this year, although the value of Sales General And Administrative To Revenue will most likely fall to 0.24.

	2021	2022	2023	2024 (projected)
Gross Profit	1.4B	1.6B	1.8B	1.8B
Total Revenue	1.4B	1.6B	1.8B	1.9B

Gross Profit Total Revenue

Exelixis fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Common Stock Shares Outstanding	Other Stockholder Equity	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Other Assets	Long Term Debt
Total Assets		0.99	0.72	0.61	0.61	-0.3	0.88	0.85	0.85	-0.68	0.95	0.75	0.95	0.86	0.94	0.94	0.96	-0.21	0.89	0.34	0.96	-0.35	-0.33	-0.03	0.95	-0.55
Total Stockholder Equity	0.99		0.78	0.61	0.62	-0.41	0.83	0.78	0.8	-0.76	0.92	0.77	0.92	0.79	0.95	0.95	0.97	-0.34	0.84	0.2	0.97	-0.4	-0.26	-0.09	0.95	-0.61
Retained Earnings	0.72	0.78		0.08	0.25	-0.51	0.63	0.46	0.64	-0.61	0.67	0.49	0.7	0.63	0.66	0.69	0.69	-0.56	0.55	-0.18	0.68	-0.61	0.34	-0.35	0.74	-0.58
Common Stock Shares Outstanding	0.61	0.61	0.08		0.78	-0.27	0.37	0.5	0.3	-0.63	0.51	0.73	0.46	0.28	0.71	0.64	0.66	-0.09	0.52	0.38	0.69	-0.04	-0.67	0.24	0.54	-0.4
Other Stockholder Equity	0.61	0.62	0.25	0.78		-0.09	0.42	0.32	0.36	-0.5	0.53	0.68	0.51	0.36	0.64	0.59	0.59	0.01	0.34	0.29	0.64	-0.16	-0.59	-0.23	0.57	-0.07
Short Long Term Debt Total	-0.3	-0.41	-0.51	-0.27	-0.09		-0.06	-0.1	-0.09	0.78	-0.2	-0.35	-0.16	-0.02	-0.4	-0.48	-0.4	0.86	-0.15	0.57	-0.41	0.47	-0.32	-0.19	-0.34	0.87
Other Current Liab	0.88	0.83	0.63	0.37	0.42	-0.06		0.91	0.85	-0.46	0.94	0.62	0.86	0.92	0.8	0.84	0.81	0.01	0.9	0.52	0.82	-0.23	-0.25	-0.01	0.79	-0.36
Total Current Liabilities	0.85	0.78	0.46	0.5	0.32	-0.1	0.91		0.82	-0.46	0.88	0.57	0.83	0.86	0.77	0.81	0.79	0.01	0.95	0.59	0.79	-0.18	-0.37	0.27	0.76	-0.5
Property Plant And Equipment Net	0.85	0.8	0.64	0.3	0.36	-0.09	0.85	0.82		-0.32	0.91	0.38	0.96	0.98	0.64	0.75	0.7	0.07	0.78	0.45	0.68	-0.22	-0.16	0.09	0.86	-0.42
Net Debt	-0.68	-0.76	-0.61	-0.63	-0.5	0.78	-0.46	-0.46	-0.32		-0.55	-0.86	-0.47	-0.32	-0.82	-0.82	-0.76	0.66	-0.52	0.15	-0.82	0.42	0.07	-0.06	-0.62	0.77
Accounts Payable	0.95	0.92	0.67	0.51	0.53	-0.2	0.94	0.88	0.91	-0.55		0.63	0.94	0.93	0.86	0.89	0.89	-0.08	0.91	0.43	0.88	-0.26	-0.25	0.04	0.9	-0.49
Cash	0.75	0.77	0.49	0.73	0.68	-0.35	0.62	0.57	0.38	-0.86	0.63		0.54	0.43	0.89	0.8	0.79	-0.3	0.62	0.24	0.88	-0.25	-0.36	-0.07	0.63	-0.43
Non Current Assets Total	0.95	0.92	0.7	0.46	0.51	-0.16	0.86	0.83	0.96	-0.47	0.94	0.54		0.93	0.79	0.85	0.84	-0.06	0.84	0.39	0.82	-0.29	-0.27	-0.02	0.95	-0.46
Non Currrent Assets Other	0.86	0.79	0.63	0.28	0.36	-0.02	0.92	0.86	0.98	-0.32	0.93	0.43	0.93		0.67	0.76	0.72	0.13	0.83	0.53	0.71	-0.23	-0.18	0.08	0.82	-0.36
Cash And Short Term Investments	0.94	0.95	0.66	0.71	0.64	-0.4	0.8	0.77	0.64	-0.82	0.86	0.89	0.79	0.67		0.93	0.98	-0.33	0.85	0.25	1.0	-0.37	-0.36	-0.04	0.84	-0.57
Net Receivables	0.94	0.95	0.69	0.64	0.59	-0.48	0.84	0.81	0.75	-0.82	0.89	0.8	0.85	0.76	0.93		0.91	-0.36	0.81	0.21	0.95	-0.34	-0.28	0.03	0.92	-0.66
Short Term Investments	0.96	0.97	0.69	0.66	0.59	-0.4	0.81	0.79	0.7	-0.76	0.89	0.79	0.84	0.72	0.98	0.91		-0.33	0.89	0.24	0.98	-0.4	-0.33	-0.03	0.87	-0.6
Non Current Liabilities Total	-0.21	-0.34	-0.56	-0.09	0.01	0.86	0.01	0.01	0.07	0.66	-0.08	-0.3	-0.06	0.13	-0.33	-0.36	-0.33		-0.08	0.74	-0.33	0.47	-0.42	0.22	-0.28	0.69
Other Current Assets	0.89	0.84	0.55	0.52	0.34	-0.15	0.9	0.95	0.78	-0.52	0.91	0.62	0.84	0.83	0.85	0.81	0.89	-0.08		0.5	0.86	-0.24	-0.32	0.17	0.79	-0.52
Total Liab	0.34	0.2	-0.18	0.38	0.29	0.57	0.52	0.59	0.45	0.15	0.43	0.24	0.39	0.53	0.25	0.21	0.24	0.74	0.5		0.25	0.22	-0.57	0.33	0.19	0.2
Total Current Assets	0.96	0.97	0.68	0.69	0.64	-0.41	0.82	0.79	0.68	-0.82	0.88	0.88	0.82	0.71	1.0	0.95	0.98	-0.33	0.86	0.25		-0.37	-0.34	-0.03	0.87	-0.59
Short Term Debt	-0.35	-0.4	-0.61	-0.04	-0.16	0.47	-0.23	-0.18	-0.22	0.42	-0.26	-0.25	-0.29	-0.23	-0.37	-0.34	-0.4	0.47	-0.24	0.22	-0.37		-0.15	0.14	-0.33	0.43
Common Stock	-0.33	-0.26	0.34	-0.67	-0.59	-0.32	-0.25	-0.37	-0.16	0.07	-0.25	-0.36	-0.27	-0.18	-0.36	-0.28	-0.33	-0.42	-0.32	-0.57	-0.34	-0.15		-0.16	-0.25	-0.19
Other Liab	-0.03	-0.09	-0.35	0.24	-0.23	-0.19	-0.01	0.27	0.09	-0.06	0.04	-0.07	-0.02	0.08	-0.04	0.03	-0.03	0.22	0.17	0.33	-0.03	0.14	-0.16		-0.1	-0.4
Other Assets	0.95	0.95	0.74	0.54	0.57	-0.34	0.79	0.76	0.86	-0.62	0.9	0.63	0.95	0.82	0.84	0.92	0.87	-0.28	0.79	0.19	0.87	-0.33	-0.25	-0.1		-0.55
Long Term Debt	-0.55	-0.61	-0.58	-0.4	-0.07	0.87	-0.36	-0.5	-0.42	0.77	-0.49	-0.43	-0.46	-0.36	-0.57	-0.66	-0.6	0.69	-0.52	0.2	-0.59	0.43	-0.19	-0.4	-0.55

Click cells to compare fundamentals

Exelixis Account Relationship Matchups

Exelixis fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.9B	2.1B	2.6B	3.1B	2.9B	3.1B
Total Stockholder Equity	1.7B	1.9B	2.2B	2.5B	2.3B	2.4B
Retained Earnings	(559.4M)	(447.6M)	(216.5M)	(34.2M)	(173.4M)	(182.0M)
Common Stock Shares Outstanding	315.0M	318.0M	322.4M	324.6M	321.5M	178.5M
Liabilities And Stockholders Equity	1.9B	2.1B	2.6B	3.1B	2.9B	3.1B
Other Stockholder Equity	2.2B	2.3B	2.4B	2.5B	2.4B	1.4B
Short Long Term Debt Total	50.7M	49.1M	51.3M	190.2M	189.9M	156.7M
Other Current Liab	21.7M	176.2M	313.3M	267.5M	329.4M	345.9M
Total Current Liabilities	142.7M	204.7M	337.6M	324.4M	394.3M	414.0M
Property Plant And Equipment Net	90.7M	67.4M	104.0M	401.2M	470.9M	494.4M
Net Debt	(215.8M)	(270.1M)	(595.9M)	(311.0M)	(73.1M)	(69.4M)
Accounts Payable	11.6M	23.6M	24.3M	32.7M	33.8M	35.5M
Cash	266.5M	319.2M	647.2M	501.2M	263.0M	190.9M
Non Current Assets Total	874.5M	691.9M	781.5M	1.5B	1.6B	1.7B
Non Currrent Assets Other	11.3M	71.9M	131.0M	290.6M	334.2M	350.9M
Cash And Short Term Investments	852.2M	1.2B	1.5B	1.3B	995.3M	1.0B
Net Receivables	119.1M	160.9M	282.7M	214.8M	237.4M	249.3M
Short Term Investments	585.7M	887.3M	819.9M	807.3M	732.3M	768.9M
Non Current Liabilities Total	57.0M	53.6M	68.0M	258.7M	284.2M	213.1M
Other Current Assets	27.0M	57.0M	57.5M	62.2M	67.9M	71.3M
Total Liab	199.7M	258.2M	405.6M	583.1M	678.4M	370.3M
Total Current Assets	1.0B	1.4B	1.8B	1.6B	1.3B	1.4B
Accumulated Other Comprehensive Income	3.1M	4.5M	(758K)	(14.5M)	(3.8M)	(3.9M)
Short Term Debt	2.7M	3.0M	(8.7M)	17.7M	25.7M	49.6M
Common Stock	305K	312K	319K	324K	303K	287.9K
Other Liab	8.9M	4.5M	16.8M	68.5M	78.8M	83.4M
Other Assets	185.3M	187.1M	197.5M	286.9M	329.9M	346.4M
Common Stock Total Equity	300K	305K	312K	324K	372.6K	391.2K
Inventory	12.9M	21.0M	27.5M	33.3M	17.3M	9.5M
Property Plant And Equipment Gross	90.7M	67.4M	144.9M	462.1M	551.2M	578.8M
Property Plant Equipment	48.9M	67.4M	149.2M	110.6M	127.2M	133.6M
Current Deferred Revenue	106.7M	1.8M	8.7M	6.6M	5.4M	5.1M
Net Tangible Assets	1.6B	1.8B	2.0B	2.4B	2.8B	2.9B
Retained Earnings Total Equity	(880.4M)	(559.4M)	(447.6M)	(34.2M)	(39.4M)	(41.3M)
Capital Surpluse	2.2B	2.2B	2.3B	2.5B	2.9B	2.1B

Pair Trading with Exelixis

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Exelixis position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exelixis will appreciate offsetting losses from the drop in the long position's value.

Moving together with Exelixis Stock

0.72	VKTX	Viking Therapeutics	Pair Corr
0.67	DYAI	Dyadic International Financial Report 8th of May 2024	Pair Corr

Moving against Exelixis Stock

0.83	ORGO	Organogenesis Holdings Earnings Call This Week	Pair Corr
0.78	OVID	Ovid Therapeutics	Pair Corr
0.75	LFCR	Lifecore Biomedical Financial Report 6th of June 2024	Pair Corr
0.66	GNLX	Genelux Common	Pair Corr
0.58	EVOK	Evoke Pharma	Pair Corr

The ability to find closely correlated positions to Exelixis could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Exelixis when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Exelixis - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Exelixis to buy it.

The correlation of Exelixis is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Exelixis moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Exelixis moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Exelixis can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Exelixis is a strong investment it is important to analyze Exelixis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Exelixis' future performance. For an informed investment choice regarding Exelixis Stock, refer to the following important reports:

How To Invest In Exelixis

Details

Is Exelixis Stock a good investment?

Details

What is Exelixis' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.

Note that the Exelixis information on this page should be used as a complementary analysis to other Exelixis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Exelixis Stock analysis

When running Exelixis' price analysis, check to measure Exelixis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Exelixis is operating at the current time. Most of Exelixis' value examination focuses on studying past and present price action to predict the probability of Exelixis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Exelixis' price. Additionally, you may evaluate how the addition of Exelixis to your portfolios can decrease your overall portfolio volatility.

	Global Correlations Find global opportunities by holding instruments from different markets
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Transaction History View history of all your transactions and understand their impact on performance
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets

Is Exelixis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

0.65

Revenue Per Share

5.914

Quarterly Revenue Growth

0.04

Return On Assets

0.043

Return On Equity

0.0876

The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Exelixis Cost Of Revenue vs Interest Expense Analysis

Cost Of Revenue vs Interest Expense

Cost Of Revenue vs Interest Expense Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Interest Expense

Exelixis fundamental ratios Correlations

Exelixis Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Exelixis fundamental ratios Accounts

Pair Trading with Exelixis

Moving together with Exelixis Stock

Moving against Exelixis Stock

Complementary Tools for Exelixis Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Non Currrent Assets Other	+ 0.98	Property Plant And Equipment Net
Short Term Investments	+ 0.98	Cash And Short Term Investments
Total Current Assets	+ 0.98	Short Term Investments
Short Term Investments	+ 0.97	Total Stockholder Equity

Cash	- 0.86	Net Debt
Total Current Assets	- 0.82	Net Debt
Net Receivables	- 0.82	Net Debt
Cash And Short Term Investments	- 0.82	Net Debt
Short Term Investments	- 0.76	Net Debt
Net Debt	- 0.76	Total Stockholder Equity